Posted on 01/21/2023 8:09:35 PM PST by SeekAndFind
BEIJING, Jan 20 (Reuters) - Sinopharm (1099.HK) said on Friday its biotech unit has received regulatory approval for clinical trials of its mRNA COVID-19 vaccine targeting the Omicron variant.
The unit, based in the commercial hub of Shanghai, has built a research and development platform, as well as workshops with annual production capacity of 2 billion doses of mRNA vaccine, Sinopharm said.
Sinopharm, now the China distributor of Merck & Co's (MRK.N) COVID-19 antiviral treatment molnupiravir, said its biotech unit received clinical trial approval from the National Medical Products Administration.
Several homegrown mRNA candidates are being studied in China but none has been approved for use. Sinopharm unit China National Biotec Group Co Ltd said it had designed an mRNA candidate targeting the Omicron variant of the coronavirus.
The news comes a week after Merck's molnupiravir was launched in the Chinese market. Merck had said Sinopharm was the only legally authorised distributor of the treatment in China, sold under the brand name Lagevrio.
(Excerpt) Read more at reuters.com ...
I had Omicron in June and had the flu two weeks ago. The seasonal flu was far worse in terms of symptoms and duration.
How do you say “died suddenly” in Mandarin?
Population reduction in China.
was the flu the RSV one wherre it hits the lungs hard?
I don’t think so, it was mostly in my sinuses
Oh yeah, from red China? the people who brought you the antifreeze dog treats and toothpaste, radioactive drywall, and formaldehyde candy?
Yeah, lemme roll up my sleeve lol.
Thanks. I’m dreading getting the lung flu. I don’t do well with those type. Although omicron supposedly was supposed to hit the lungs, it didn’t when i got it
" Sinopharm (1099.HK) said on Friday its biotech unit has received regulatory approval for clinical trials of its mRNA COVID-19 vaccine targeting the Omicron variant.
The unit, based in the commercial hub of Shanghai, has built a research and development platform,
as well as workshops with annual production capacity of 2 billion doses of mRNA vaccine, Sinopharm said. Sinopharm,
now the China distributor of Merck & Co's (MRK.N) COVID-19 antiviral treatment molnupiravir,
said its biotech unit received clinical trial approval from the National Medical Products Administration."
China cooks up a home made vax. What could go wrong?
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.